Effects of intravenous thrombolysis with recombinant staphylokinase on platelet activation parameters in patients with acute myocardial infarction
- VernacularTitle:重组葡激酶静脉溶栓治疗对急性心肌梗塞患者血小板活化的作用
- Author:
Shuo LU
;
Shumei LI
;
Yan CUI
- Publication Type:Journal Article
- Keywords:
myocardial infarction/drug therapy;
recombinant staphylokinase;
thrombin-antithrombin complex;
alpha granule membrane protein;
thrombolytic therapy
- From:
Journal of Jilin University(Medicine Edition)
2006;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of recombinant staphylokinase (r-SAK) on platelet activation parameters in patients with acute myocardial infarction(AMI) by intravenous thrombolysis in order to investigate the clinical thrombolytic efficacy of r-SAK therapy in AMI comparing with recombinant tissue-type plasminogen activator(rt-PA) therapy.Methods Thirty-three patients with AMI within 12 h after the onset were selected and divided randomly into the r-SAK therapy group(n=17) and rt-PA therapy group(n=16).Coronary artery angiography(CAG) was performed 90 min after thrombolytic therapy in patients.Thrombin-antithrombin complex(TAT) and alpha granule membrane protein(GMP-140) were measured by similar commercial enzyme-linked immunosorbent assay(ELISA).Results In r-SAK group and rt-PA group,the plasma contents of GMP-140 2 h after thrombolytic therapy were significantly higher than before therapy(P0.05).In rt-PA group,the plasma content of TAT 2 h after thrombolytic therapy increased significantly(P0.05).) Conclusion r-SAK has similar effect with rt-PA and it will become available for highly fibrin-selective thrombolytic therapy of AMI.Thrombolytic treatment with r-SAK can improve the injury of myocardial microperfusion.
